Geriatric Determinants of General Repercussion of Radiotherapy for Patient Over 75 Years With Prostate Cancer (PROGERAD)

May 29, 2018 updated by: Institut Cancerologie de l'Ouest

Patient Over 75 Years With Prostate Cancer: Geriatric Determinants of General Repercussion of Radiotherapy With Curative Intent

The investigators propose to carry out a prospective analysis of physical impact, psychological, cognitive and social of radiotherapy in all patients over 75 years bearer of localized prostate cancer with an indication of curative radiotherapy. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities . The quality of life of patients will be evaluated by the QLQ C30 (Quality of Life Questionnaire) European Organisation for Research and Treatment of Cancer (EORTC) before starting treatment, at the end of radiotherapy (2 months) and at 6 months. This short follow-up period seems appropriate in this elderly population and will allow an answer within 2 years to the problem raised in clinical practice.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

230

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Angers, France, 49055
        • Institut de Cancérologie de l'Ouest
      • Creteil, France, 94000
        • Hopital Henri Mondor
      • Dijon, France, 21079
        • Centre Georges François Leclerc
      • La Roche Sur Yon, France, 85925
        • CHD
      • Lorient, France, 56100
        • Centre Hospitalier Bretagne Sud
      • Nantes, France, 44202
        • Centre Catherine de Sienne
      • St Brieuc, France, 22015
        • Clinique Armoricaine de Radiologie
      • St Gregoire, France, 35760
        • CHP
      • St Nazaire, France, 44606
        • Clinique Mutualiste de l'Estuaire
      • St Priest En Jarez, France, 42270
        • Institut de Cancérologie de Loire

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

75 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  1. Man with a histologically proven prostate cancer
  2. Indication of a curative intent radiotherapy
  3. Age ≥ 75 years
  4. Patient who signed an informed consent

Exclusion Criteria:

  1. Patient with metastatic prostate cancer
  2. Patient unable to submit to monitoring of the protocol for social, geographical or family reasons
  3. A person who is not affiliated to a social security scheme or of such a scheme
  4. Patient under trusteeship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: geriatric assessment and quality of life

Included patient must have a geriatric assessment before radiotherapy and 6 months later.

Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later.
Other: geriatric assessment and quality of life

Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .

Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later.

Radiation: Radiotherapy
standard radiotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
General tolerance of the radiotherapy evaluated by the QLQ-C30 questionnaire
Time Frame: 2 months
Tolerance will be called bad for the loss of 20 or more points (out of 100) between the initial assessment and evaluations at 2 and 6 months. Tolerance will be called correct in other cases. This threshold of 20 points was selected according to the work of Osoba.
2 months
Complete geriatric assessment
Time Frame: 6 months
This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .
6 months
General tolerance of the radiotherapy evaluated by the QLQ-C30 questionnaire
Time Frame: 6 months
Tolerance will be called bad for the loss of 20 or more points (out of 100) between the initial assessment and evaluations at 2 and 6 months. Tolerance will be called correct in other cases. This threshold of 20 points was selected according to the work of Osoba.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut Cancerologie de l'Ouest

Investigators

  • Principal Investigator: STEPHANE SUPIOT, MD, Institut de Cancérologie de l'Ouest
  • Principal Investigator: Aurore GOINEAU, MD, Institut de Cancérologie de l'Ouest

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2015

Primary Completion (Actual)

February 1, 2017

Study Completion (Actual)

August 1, 2017

Study Registration Dates

First Submitted

July 22, 2016

First Submitted That Met QC Criteria

August 17, 2016

First Posted (Estimate)

August 23, 2016

Study Record Updates

Last Update Posted (Actual)

May 31, 2018

Last Update Submitted That Met QC Criteria

May 29, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ICO-A-2014-04
  • 2014-A00300-47 (Other Identifier: French Health Products Safety Agency)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe